|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Wednesday, November 22, 2006
MCT-125 human trial: MultiCell requests permission for MS trial or fatigue
MultiCell Technologies has said that it will seek authorization to proceed with its phase IIb MCT-125 human trial for fatigue in multiple sclerosis in the UK. MCT-125 has already completed a phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in multiple sclerosis patients. There is no drug specifically approved for the treatment of chronic fatigue in multiple sclerosis patients.MORE |